

Short™ AE-IGF-1

Insulin-like Growth Factor 1

Product Performance

ADDITION OF IGF-1 TO PRODUCTION MEDIA

IGF-1 is often added to culture media to improve growth characteristics and protein production of manufacturing cell lines.



However,

- Reliance on powdered format adds handling steps and therefore variability to a process.
- High price increases manufacturing costs of any product.

NOVEL PRODUCTION PROCESS FROM CellRx

A highly efficient patented process that produces modified IGF-1 (**Short AE-IGF-1**) in a stable liquid format at a competitive price.

- Short AE-IGF-1 is available in liquid format, allowing batch media preparation which eliminates the need for mixing of powder at bulk scale.
- Short AE-IGF-1 reduces the cost of upstream manufacturing processes.



- **Performance** of Short AE-IGF-1 matches industry leading IGF-1 to improve culture performance.
- Available at a **fraction of the cost** of alternatives.*
- Validated **4 years stability** in liquid format, reducing handling and therefore variability.
- Samples available as part of the **evaluation program** for qualifying customers.

cGMP compliant production using a fully defined animal component free process.

Technical support available from cell culture specialists with more than **25 years** of process development expertise.

Short™ AE-IGF-1 is a registered trademark of CellRx Limited
LONG® is a registered trademark of Novozymes Biopharma AU

E-MAIL US TODAY FOR A QUOTE
info@cellrxbio.com

CellRx

CellRx Limited
12-14 Finch Road, Douglas, Isle of Man. Tel: +44 1223 364 412

cellrxbio.com